Pharmacogenetics, pharmacogenomics and airway disease.
The availability of a draft sequence for the human genome will revolutionise research into airway disease. This review deals with two of the most important areas impinging on the treatment of patients: pharmacogenetics and pharmacogenomics. Considerable inter-individual variation exists at the DNA level in targets for medication, and variability in response to treatment may, in part, be determined by this genetic variation. Increased knowledge about the human genome might also permit the identification of novel therapeutic targets by expression profiling at the RNA (genomics) or protein (proteomics) level. This review describes recent advances in pharmacogenetics and pharmacogenomics with regard to airway disease.
Hall
Ian P
IP
Queens Medical Centre, Nottingham, UK. ian.hall@nottingham.ac.uk
D000818:Animals; D016503:Drug Delivery Systems / Q000379:methods; D015894:Genome, Human / Q000235:genetics; D006801:Humans; D010597:Pharmacogenetics / Q000379:methods* / Q000639:trends*; D012120:Respiration Disorders / Q000188:drug therapy* / Q000235:genetics*; D019141:Respiratory System Agents / Q000008:administration & dosage* / Q000627:therapeutic use
D019141:Respiratory System Agents